LOGIN  |  REGISTER
Viking Therapeutics

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 112.76
-2.23 -1.94
803,524
1.73B
US$ 195.070B
US$ 542.94
3.19 0.59
408,353
356.18M
US$ 193.380B
US$ 95.31
0.70 0.74
1.18M
1.47B
US$ 140.100B
US$ 360.56
-0.43 -0.12
197,380
381.22M
US$ 137.450B
US$ 84.87
3.08 3.77
4.23M
1.28B
US$ 108.630B
US$ 234.28
-1.91 -0.81
625,077
290.01M
US$ 67.940B
US$ 71.04
-0.06 -0.08
557,198
589.80M
US$ 41.900B
US$ 82.75
-0.64 -0.77
196,295
494.60M
US$ 40.930B
US$ 228.88
-1.38 -0.60
155,040
146.80M
US$ 33.600B
US$ 331.45
-8.15 -2.40
102,443
72.42M
US$ 24.000B
US$ 104.49
-1.00 -0.95
338,039
199.07M
US$ 20.800B
US$ 205.79
-1.58 -0.76
98,805
98.71M
US$ 20.310B
US$ 264.92
-3.07 -1.15
51,721
70.14M
US$ 18.580B
US$ 89.30
-1.98 -2.17
415,621
199.58M
US$ 17.820B
US$ 70.23
-0.07 -0.10
529,243
226.94M
US$ 15.940B
US$ 30.42
-0.08 -0.26
1.59M
510.59M
US$ 15.530B
US$ 23.85
-0.17 -0.71
240,128
435.99M
US$ 10.400B
US$ 87.27
0.09 0.10
310,802
113.74M
US$ 9.930B
US$ 248.05
1.12 0.45
69,203
38.38M
US$ 9.520B
US$ 61.23
-1.72 -2.73
372,766
151.60M
US$ 9.280B
US$ 166.23
0.66 0.40
50,161
53.54M
US$ 8.900B
US$ 152.15
-6.29 -3.97
178,827
56.03M
US$ 8.520B
US$ 152.28
0.41 0.27
71,586
55.14M
US$ 8.400B
US$ 178.84
0.30 0.17
60,003
46.44M
US$ 8.310B
US$ 346.86
-4.84 -1.38
37,707
22.92M
US$ 7.950B
US$ 17.05
-0.32 -1.84
184,759
352.16M
US$ 6.000B
US$ 97.21
1.57 1.64
108,244
58.28M
US$ 5.670B
US$ 172.19
-3.25 -1.85
181,839
29.97M
US$ 5.160B
US$ 79.35
0.01 0.01
2.62M
58.54M
US$ 4.650B
US$ 137.32
2.16 1.60
37,410
33.54M
US$ 4.610B
US$ 80.65
-2.26 -2.73
113,166
54.11M
US$ 4.360B
US$ 79.28
-0.13 -0.16
66,288
50.22M
US$ 3.980B
US$ 158.28
0.12 0.08
25,870
24.48M
US$ 3.870B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 97.96
3.37 3.56
150,605
31.30M
US$ 3.070B
US$ 26.70
-0.68 -2.48
225,599
108.20M
US$ 2.890B
US$ 47.58
0.26 0.55
112,088
54.30M
US$ 2.580B
US$ 24.60
-0.50 -1.99
370,041
101.66M
US$ 2.500B
US$ 35.96
-0.26 -0.72
122,950
65.68M
US$ 2.360B
US$ 51.23
-1.04 -1.99
66,505
45.69M
US$ 2.340B
US$ 63.86
-0.20 -0.31
1.30M
33.56M
US$ 2.140B
US$ 94.42
0.25 0.27
15,477
22.48M
US$ 2.120B
US$ 67.30
-2.20 -3.17
53,956
30.89M
US$ 2.080B
US$ 21.77
-0.52 -2.33
46,415
77.16M
US$ 1.680B
US$ 34.40
0.01 0.03
211,496
48.75M
US$ 1.680B
US$ 10.85
-0.03 -0.28
487,314
141.77M
US$ 1.540B
US$ 10.19
-0.14 -1.36
99,319
134.56M
US$ 1.370B
US$ 8.63
0.06 0.70
152,680
146.95M
US$ 1.270B
US$ 26.71
-0.26 -0.96
54,660
46.39M
US$ 1.240B
US$ 29.31
-0.03 -0.10
30,493
41.92M
US$ 1.230B
US$ 15.75
-0.22 -1.38
151,871
76.25M
US$ 1.200B
US$ 29.43
-1.29 -4.20
112,145
40.30M
US$ 1.190B
US$ 17.72
-0.30 -1.66
18,135
61.52M
US$ 1.090B
US$ 21.58
-0.35 -1.60
84,584
49.60M
US$ 1.070B
US$ 21.56
-0.92 -4.09
126,365
49.28M
US$ 1.060B
US$ 7.17
-0.04 -0.55
239,705
128.81M
US$ 923.570M
US$ 32.06
-1.65 -4.89
440,441
28.76M
US$ 922.050M
US$ 9.62
-1.12 -10.43
246,637
83.72M
US$ 804.970M
US$ 18.00
-0.25 -1.37
169,109
44.01M
US$ 792.180M
US$ 57.25
0.74 1.31
9,322
12.67M
US$ 725.360M
US$ 15.52
-0.28 -1.77
53,942
45.96M
US$ 713.300M
US$ 17.42
0.05 0.29
40,791
38.21M
US$ 665.620M
US$ 15.21
-1.02 -6.28
139,126
41.94M
US$ 637.910M
US$ 3.33
-0.02 -0.72
1.74M
186.64M
US$ 620.760M
US$ 17.97
-0.60 -3.23
251,587
33.60M
US$ 603.790M
US$ 9.02
-0.14 -1.53
54,211
65.37M
US$ 589.640M
US$ 23.64
-1.36 -5.44
73,050
24.22M
US$ 572.560M
US$ 13.54
0.16 1.20
93,639
41.23M
US$ 558.250M
US$ 8.01
-0.35 -4.19
75,732
62.30M
US$ 499.020M
US$ 4.67
-0.24 -4.89
357,771
105.48M
US$ 492.590M
US$ 53.05
0.35 0.66
105,146
9.27M
US$ 491.770M
US$ 12.10
-0.36 -2.89
334,293
40.63M
US$ 491.620M
US$ 7.49
0.10 1.35
1.97M
58.52M
US$ 438.020M
US$ 0.73
-0.02 -2.53
13.30M
595.33M
US$ 435.190M
US$ 12.67
-0.12 -0.94
89,163
33.02M
US$ 418.360M
US$ 17.32
0.12 0.70
46,262
24.00M
US$ 415.680M
US$ 16.02
0.98 6.52
251,026
24.26M
US$ 388.650M
US$ 13.51
-0.13 -0.95
9,464
27.60M
US$ 372.880M
US$ 11.87
-0.24 -1.98
20,720
29.85M
US$ 354.320M
US$ 9.15
0.04 0.44
757,235
38.52M
US$ 352.460M
US$ 9.35
0.02 0.21
34,273
37.43M
US$ 349.970M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 7.86
-0.06 -0.76
24,708
38.94M
US$ 306.070M
US$ 32.20
-0.26 -0.80
8,689
8.74M
US$ 281.430M
US$ 6.90
-0.16 -2.27
71,127
39.49M
US$ 272.280M
US$ 3.64
-0.07 -1.76
353,449
74.59M
US$ 271.130M
US$ 30.90
0.43 1.41
26,203
8.46M
US$ 261.410M
US$ 10.90
0.57 5.52
168,224
23.82M
US$ 259.640M
US$ 28.75
2.50 9.52
8,463
8.53M
US$ 245.240M
US$ 7.65
-0.12 -1.54
24,538
31.85M
US$ 243.650M
US$ 8.83
0.00 0.00
44,697
26.22M
US$ 231.390M
US$ 7.34
-0.11 -1.48
66,028
30.03M
US$ 220.300M
US$ 2.19
-0.06 -2.46
236,518
100.56M
US$ 219.720M
US$ 3.25
-0.16 -4.56
300,102
67.59M
US$ 219.330M
US$ 3.27
0.30 10.10
239,214
64.80M
US$ 211.900M
US$ 61.57
0.54 0.88
4,975
3.39M
US$ 208.710M
US$ 6.03
0.03 0.50
144,214
33.70M
US$ 203.210M
US$ 10.01
0.58 6.15
67,098
18.81M
US$ 188.290M
US$ 3.95
0.00 0.00
10,588
45.84M
US$ 181.070M
US$ 2.07
-0.02 -0.72
60,372
84.73M
US$ 174.970M
US$ 3.30
0.06 1.85
27,867
50.40M
US$ 166.320M
US$ 7.82
-0.09 -1.14
34,636
21.26M
US$ 166.150M
US$ 1.06
0.15 16.48
281,974
156.55M
US$ 165.940M
US$ 46.00
-0.74 -1.58
3,705
3.26M
US$ 149.960M
US$ 3.87
-0.17 -4.09
223,124
37.47M
US$ 144.820M
US$ 2.90
-0.03 -1.02
177,796
49.56M
US$ 143.720M
US$ 4.62
-0.29 -5.92
4,144
30.49M
US$ 140.710M
US$ 3.03
-0.03 -0.98
14,777
43.09M
US$ 130.560M
US$ 2.75
-0.03 -1.08
9,576
39.39M
US$ 108.320M
US$ 6.61
0.23 3.61
127,350
16.39M
US$ 108.260M
US$ 15.91
0.47 3.04
31,853
6.55M
US$ 104.240M
US$ 3.24
0.11 3.51
5,719
30.25M
US$ 98.010M
US$ 15.12
-0.01 -0.07
951
6.27M
US$ 94.800M
US$ 7.99
-0.07 -0.87
13,187
11.61M
US$ 92.760M
US$ 2.03
0.05 2.53
42,684
43.62M
US$ 88.550M
US$ 2.48
0.03 1.22
2,456
34.31M
US$ 85.090M
US$ 1.09
0.01 0.93
46,121
77.89M
US$ 84.900M
US$ 2.09
0.02 1.16
1,502
37.10M
US$ 77.690M
US$ 4.50
0.00 0.00
2,037
16.04M
US$ 72.180M
US$ 0.51
0.01 2.60
29,385
139.01M
US$ 71.310M
US$ 1.28
0.11 8.94
410,306
55.50M
US$ 71.040M
US$ 1.18
-0.02 -1.75
31,366
59.23M
US$ 69.830M
US$ 1.99
-0.02 -1.00
87,359
34.82M
US$ 69.290M
C$ 0.28
-0.02 -5.17
85,700
247.78M
C$ 68.140M
US$ 12.93
-0.46 -3.44
13,308
5.25M
US$ 67.880M
US$ 2.60
-0.05 -1.89
877
26.08M
US$ 67.810M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 1.04
-0.01 -0.95
60,822
54.95M
US$ 57.150M
US$ 1.52
0.03 1.68
1,755
37.64M
US$ 57.020M
US$ 3.24
0.05 1.57
6,607
17.54M
US$ 56.830M
US$ 0.97
-0.01 -1.02
6,002
57.89M
US$ 56.150M
US$ 0.13
-0.02 -10.71
209,692
417.59M
US$ 52.200M
US$ 1.26
0.00 0.00
17,577
40.14M
US$ 50.580M
US$ 19.69
-0.11 -0.56
5,317
2.53M
US$ 49.820M
US$ 0.81
-0.008 -0.98
41,253
59.34M
US$ 48.010M
C$ 0.39
0.00 0.00
0
119.77M
C$ 46.110M
C$ 0.47
-0.005 -1.06
5,000
93.38M
C$ 43.420M
US$ 1.11
0.005 0.45
237,383
37.72M
US$ 41.680M
US$ 0.79
-0.02 -2.70
566,227
52.54M
US$ 41.300M
US$ 1.99
-0.02 -1.00
374,539
20.75M
US$ 41.290M
C$ 0.35
-0.01 -2.78
6,545
113.10M
C$ 39.580M
US$ 2.74
0.23 9.08
392,868
13.30M
US$ 36.420M
US$ 5.45
2.34 75.24
101
6.63M
US$ 36.130M
US$ 1.14
0.02 1.79
229,631
30.84M
US$ 35.160M
C$ 0.44
0.00 0.00
0
77.42M
C$ 34.060M
US$ 1.47
-0.11 -7.13
30,804
20.24M
US$ 29.750M
US$ 4.85
0.00 0.00
62,519
5.89M
US$ 28.570M
US$ 1.64
-0.14 -7.87
3.12M
16.93M
US$ 27.770M
US$ 1.64
0.002 0.12
12,496
16.64M
US$ 27.210M
US$ 0.36
-0.0026 -0.72
246,489
72.19M
US$ 25.990M
US$ 1.08
0.03 2.86
28,406
22.90M
US$ 24.730M
US$ 3.47
-0.07 -1.84
14,579
6.79M
US$ 23.530M
US$ 0.75
-0.0048 -0.64
9,988
29.94M
US$ 22.460M
US$ 1.29
-0.12 -8.51
66,685
17.23M
US$ 22.230M
US$ 0.98
0.05 5.38
5,996
20.63M
US$ 20.220M
US$ 1.07
0.005 0.47
879,633
18.50M
US$ 19.700M
C$ 0.07
0.00 0.00
0
270.17M
C$ 18.910M
C$ 0.09
0.00 0.00
0
217.73M
C$ 18.510M
C$ 0.04
0.00 0.00
2.05M
451.63M
C$ 18.070M
US$ 1.60
0.09 5.71
2,190
10.54M
US$ 16.860M
US$ 0.70
-0.01 -1.70
384,988
22.00M
US$ 15.400M
C$ 0.10
0.00 0.00
0
159.67M
C$ 15.170M
US$ 1.46
-0.10 -6.28
258,790
8.81M
US$ 12.880M
US$ 3.00
0.05 1.73
295
4.17M
US$ 12.510M
US$ 0.35
0.03 10.17
173,892
31.90M
US$ 11.160M
US$ 0.67
0.04 5.98
244,291
13.96M
US$ 9.400M
US$ 0.38
0.00 0.00
0
24.39M
US$ 9.150M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.870M
US$ 1.90
-0.05 -2.51
58,716
4.46M
US$ 8.480M
US$ 4.01
0.003 0.07
15,877
2.04M
US$ 8.190M
US$ 0.40
0.0026 0.65
116,446
20.19M
US$ 8.160M
US$ 1.21
-0.07 -5.47
148,882
6.67M
US$ 8.070M
C$ 0.14
0.00 0.00
0
59.81M
C$ 8.070M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 0.60
0.00 0.00
18,821
11.07M
US$ 6.640M
US$ 1.29
-0.03 -2.27
12,845
4.39M
US$ 5.660M
US$ 0.33
0.0059 1.84
37,409
16.82M
US$ 5.500M
US$ 1.75
0.02 0.87
24,564
3.14M
US$ 5.480M
US$ 0.39
0.00 0.00
0
11.88M
US$ 4.630M
US$ 1.05
0.04 3.47
58,954
4.37M
US$ 4.570M
US$ 1.94
-0.08 -3.96
1,506
2.05M
US$ 3.980M
US$ 4.95
-0.06 -1.10
3,360
729,980
US$ 3.610M
US$ 0.44
0.00 0.00
117,606
8.00M
US$ 3.520M
US$ 1.79
0.00 0.00
0
1.82M
US$ 3.260M
US$ 3.24
0.01 0.35
6,177
980,321
US$ 3.170M
US$ 0.70
0.02 3.38
164,825
3.73M
US$ 2.620M
US$ 0.36
0.00 0.00
141,114
7.26M
US$ 2.610M
US$ 0.03
0.00 0.00
0
96.71M
US$ 2.420M
US$ 0.96
0.02 2.17
24,325
2.46M
US$ 2.360M
US$ 0.27
-0.0058 -2.09
135,567
8.27M
US$ 2.250M
US$ 0.20
0.00 0.00
0
10.59M
US$ 2.120M
US$ 3.43
-0.22 -6.00
28,667
552,854
US$ 1.900M
US$ 0.59
-0.21 -26.66
1.51M
3.20M
US$ 1.880M
US$ 0.46
-0.04 -7.33
202,824
3.75M
US$ 1.710M
US$ 0.05
0.00 0.00
0
29.91M
US$ 1.500M
US$ 3.08
2.85 1.00
800
418,049
US$ 1.290M
US$ 0.14
0.00 0.00
0
7.26M
US$ 1.020M
US$ 0.15
0.00 0.00
0
5.24M
US$ 796K
US$ 0.37
0.00 0.00
0
1.78M
US$ 659K
US$ 0.85
0.00 0.00
60,097
-
US$ -
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
0.00 0.00
0
855.04M
US$ -
US$ 6.06
0.00 0.00
16,151
-
US$ -
US$ 26.53
0.00 0.00
110,815
-
US$ -
C$ 0.73
0.00 0.00
9,000
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Device Stocks


Inspira Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology

The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood oxygenation delivery technology. We... Read more


Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024. Select Preliminary Financial Highlights Fourth quarter 2024 total... Read more


Elutia Announces Full Launch of EluPro Following Strong Initial Demand

First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators... Read more


Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024

MOUNTAIN VIEW, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results The Company’s strategic review remains ongoing with multiple... Read more


Allurion Technologies Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass. / Jan 14, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in... Read more


Merit Medical Systems Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on...

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year 2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year 2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable... Read more


Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included... Read more


Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national... Read more


Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 ACTON, Mass. / Jan 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available... Read more


Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

GOLETA, Calif. / Jan 13, 2025 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth... Read more


OrthoPediatrics Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended... Read more


Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved...

MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the... Read more


Alphatec Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook

Full-year 2024 total revenue grew 27% to approximately $611 million Expect full-year 2025 total revenue of $732 million and positive free cash flow CARLSBAD, Calif. / Jan 13, 2025 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2024. The Company also provided a financial... Read more


SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons... Read more


BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter... Read more


Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results. Preliminary, Unaudited... Read more


FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Study to be conducted under $3.6 million NIH grant  DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar... Read more


Butterfly Network and Rutgers Robert Wood Johnson Medical School Reveal Preliminary Findings from Seminal Study on Impact of POCUS in Hospital Care

Study demonstrates significant reductions in length of stay and healthcare costs, advocating for broader adoption of POCUS in hospital settings. BURLINGTON, Mass. & NEW YORK / Jan 13, 2025 / Business Wire / Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical... Read more


AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. LATHAM, N.Y. / Jan 13, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality... Read more


Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024

ENGLEWOOD, Colo. / Jan 13, 2025 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported... Read more


AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

MASON, Ohio / Jan 13, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason,... Read more


Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, N.Y. / Jan 13, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter... Read more


KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

MAHWAH, N.J. / Jan 13, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. Financial Results (unaudited) Preliminary, unaudited fourth... Read more


Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results

Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended December 31, 2024. Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected... Read more


Treace Medical Concepts Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue... Read more


CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30% Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited... Read more


Apyx Medical Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a... Read more


Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI / Jan 13, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA... Read more


Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline. “We’re focused on finding... Read more


Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland / Jan 13, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working... Read more


EDAP TMS Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems  Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar... Read more


Inspire Medical Systems Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance

MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance... Read more


Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven... Read more


MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue... Read more


CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that the Company closed the subscription... Read more


Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's...

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier... Read more


Microbot Medical Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market. Mr. Wilson’s career spans over 30 years and... Read more


Tactile Medical Appoints Laura King to Board of Directors

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record... Read more


Establishment Labs Announces CEO Transition

Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance NEW YORK / Jan 13, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José... Read more


Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Revenue of $1,021.8 Million Grows 0.9%  Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges MARLBOROUGH, Mass. / Jan 12, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approximately $1,021.8 million, an increase of 0.9% compared... Read more


RxSight Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024 Results Preliminary unaudited fourth... Read more


Microbot Medical Closes $8.6 Million Registered Direct Offering

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options.... Read more


IRadimed Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million Iradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT  WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ:... Read more


NeuroOne Medical Technologies Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for... Read more


Pulse Biosciences Appoints Paul LaViolette as Chief Executive Officer

Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI / Jan 10, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. "We are thrilled to have Paul... Read more


Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth... Read more


Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million... Read more


Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT. Management will also participate and... Read more


Inspira Technologies Preparing Production in Response to Spread of Respiratory Virus in China

RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care... Read more


EDAP TMS Appoints Joshua H. Levine to Board of Directors

AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.  “We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing... Read more